Discovery Stems From Here
Find your tools for building human cell-based models & screening assays
Welcome to Axol Bioscience
YOUR HUMAN CELL CULTURE SPECIALISTS
We provide highly validated human iPSC-derived cells and primary cells from healthy donors and patients of specific disease backgrounds, together with optimized media and growth supplements. Axol aims to develop the best human cell biology research tools to advance medical research and drug discovery. Combining our passion for science with quality, innovation and customer service, we deliver robust and reliable products that our customers need to advance their research faster.
Make the Switch to Mature Human Sensory Neurons - In 3 Weeks29 June 2021Millions of people around the world suffer from debilitating pain. However impressive advances are being made in neural stem cell R&D to advance pain research and drug discovery efforts. Robust, translational assays using human iPSC-derived Sensory Neurons enable researchers to delve deeper into the molecular pathways underpinning pain, to ultimately improve both the screening of drug candidates and the quality of life for people across the world.
Bioengineering the Human Neuromuscular Junction (NMJ)9 June 2021
Loughborough University scientists use Axol motor neurons to bioengineer a 3D human model of the neuromuscular junction (NMJ), opening the door to translational assays for use in drug development for motor neuron disease.
Can We Model Neuroimmune Diseases in a Dish?6 May 2021
Following Axol Bioscience and Censo Biotechnologies recent merger to form Axol Biosciences, our CSO Ashley Barnes was invited to speak at the Neuroimmunology Drug Development Summit alongside other experts from academia and industry on the advances being made in this burgeoning field.In this article we feature his answers to some of the pressing questions that arose from the audience and the field.
Better Assays Are Key to Understanding Neurological Conditions Caused by COVID-1927 April 2021
In a recent study from the University of Oxford, UK, and TriNetX, US, scientists explored the electronic health records of 236,379 COVID-19 patients and estimated that one-in-three COVID-19 survivors (34%) were diagnosed with a neurological or psychiatric condition within the first six months following infection.
Axol Bioscience is a Key Participant in the European Union's Horizon 2020 Research Programme24 March 2021
Axol Bioscience is a significant UK Partner in the Platforma initiative.